Lonza receives Best Ingredient Award
Basel, Switzerland - December 19, 2011
Lonza is pleased to announce that it has been awarded with the Gold Innovation Zone Best Ingredient Award for its ReGeniStem™ Red Rice at the incosmetics Asia.
This sustainable anti-aging active, derived from a meristematic culture of Himalayan Red Rice, finds application in skin care products. In vitro testing showed that the functionality of the ingredient comes from its ability to influence the epigenome of several genes important to skin barrier. In vivo efficacy testing proved its ability to increase moisture in the skin while enhancing its overall appearance. It claimed the top spot for its high material efficiency, sustainability and innovation.
Dr. Tim Schlange, Head of Personal Care from Lonza Ltd said: “We’re delighted to have won this prestigious award. A great deal of hard work goes into re-searching and developing our ingredients and so to gain recognition for our product from leading professionals within the industry is fantastic.”
The new award which has been introduced this year recognizes the development of a novel active or functional ingredient that combines innovative science and product features that demonstrate benefits to manufacturers and end-users when compared with existing ingredients.
For more information about in-cosmetics Asia visit
www.in-cosmeticsasia.com/innovationzone
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2010, the company had sales of CHF 2.680 billion.
More Information:
www.lonza.com
Lonza is pleased to announce that it has been awarded with the Gold Innovation Zone Best Ingredient Award for its ReGeniStem™ Red Rice at the incosmetics Asia.
This sustainable anti-aging active, derived from a meristematic culture of Himalayan Red Rice, finds application in skin care products. In vitro testing showed that the functionality of the ingredient comes from its ability to influence the epigenome of several genes important to skin barrier. In vivo efficacy testing proved its ability to increase moisture in the skin while enhancing its overall appearance. It claimed the top spot for its high material efficiency, sustainability and innovation.
Dr. Tim Schlange, Head of Personal Care from Lonza Ltd said: “We’re delighted to have won this prestigious award. A great deal of hard work goes into re-searching and developing our ingredients and so to gain recognition for our product from leading professionals within the industry is fantastic.”
The new award which has been introduced this year recognizes the development of a novel active or functional ingredient that combines innovative science and product features that demonstrate benefits to manufacturers and end-users when compared with existing ingredients.
For more information about in-cosmetics Asia visit
www.in-cosmeticsasia.com/innovationzone
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2010, the company had sales of CHF 2.680 billion.
More Information:
www.lonza.com
« back
